OBP Ondine Biomed

 
TIDMOBP 
 
Securityholders Approve Privatization of Ondine 
FOR:  ONDINE BIOMEDICAL INC. 
 
TSX, AIM SYMBOL:  OBP 
 
August 31, 2011 
 
Securityholders Approve Privatization of Ondine 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 31, 2011) - Ondine Biomedical Inc. (the "Company" or "Ondine") 
(TSX:OBP)(AIM:OBP) announced that at the annual general meeting of the shareholders and special meeting of 
securityholders of Ondine (collectively, the "Meeting") held today, the securityholders (the "Securityholders") 
approved the previously announced plan of arrangement (the "Arrangement") pursuant to which 0902337 B.C. Ltd. 
(the "Purchaser"), a private company whose sole shareholder is Carolyn Cross, Chairman, Chief Executive Officer 
and a shareholder of Ondine, will acquire all of the issued and outstanding common shares of Ondine (the 
"Common Shares"). In addition, at the Meeting the shareholders of Ondine (the "Shareholders") approved, among 
other things, the cancellation of the admission to trading of the Common Shares on AIM market of the London 
Stock Exchange (the "Aim Delisting"). 
 
At the Meeting, the special resolution approving the Arrangement was approved by i) approximately 97% of the 
votes cast by Securityholders present in person or represented by proxy; ii) by approximately 96% of the votes 
cast by Shareholders present in person or represented by proxy; and iii) by approximately 94% of the votes cast 
by Shareholders present in person or represented by proxy excluding the votes cast by the Purchaser and by such 
other shareholders excluded by regulatory requirements (the "Minority Shareholders"). 
 
At the Meeting, the resolution approving the AIM Delisting was approved by approximately 96% of the votes cast 
by Shareholders present in person or represented by proxy. If the Arrangement becomes effective, it is expected 
that cancellation of the admission of the Common Shares to trading on the AIM market of the London Stock 
Exchange will be at 7:00a.m. (London time) on September 7, 2011. 
 
Additional information concerning the results of the voting at the Meeting is available on SEDAR at 
www.sedar.com and on the Company's website at www.ondinebio.com. Completion of the Arrangement is subject to a 
number of conditions including, among other things, receipt of required court, and regulatory approvals. 
Subject to the satisfaction or waiver, if permissible, of such conditions to closing, it is expected the 
Arrangement will become effective on September 6, 2011. 
 
About Ondine Biomedical Inc. 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and 
viral infections. The Company is focused on developing leading edge products utilizing its patented light- 
activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection 
provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic 
resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development 
laboratory in Bothell, Washington, USA. For additional information, please visit the Company's website at: 
www.ondinebio.com. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", "expect", 
"would" and other similar expressions, are forward-looking statements that involve a number of risks and 
uncertainties. This forward-looking information relates to, among other things, the timing and prospects for 
completion of the Arrangement, which is subject to a number of conditions precedents, such as the approval of 
the Arrangement by the court, and by regulatory authorities. Accordingly, there can be no assurances that the 
Arrangement will be consummated. The forward-looking statements contained in this release reflect the current 
views of Ondine with respect to future events and are necessarily based upon a number of assumptions and 
estimates that, while considered reasonable by Ondine, are inherently subject to various risks and 
uncertainties. Many factors, both known and unknown, could cause actual results, performance or achievements to 
be materially different from the results, performance or achievements that are or may be expressed or implied 
by such forward-looking information contained in this news release and Ondine has made assumptions based on or 
related to many of these factors. Such factors that could cause actual results to differ materially from those 
projected in the Company's forward-looking statements include, without limitation, the following: litigation, 
fluctuations in economic and equity market conditions, market acceptance of our technologies and products; our 
ability to obtain financing; our financial and technical resources relative to those of our competitors; our 
ability to keep up with rapid technological change; government regulation of our technologies; our ability to 
enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and 
develop partnership opportunities; the timing of commercial product launches; the ability to achieve key 
technical milestones in key products and other risk factors identified from time to time in the Company's 
public filings. Investors are cautioned against attributing undue certainty or reliance on forward-looking 
information. Although Ondine has attempted to identify important factors that could cause actual results to 
differ materially, there may be other factors that cause results not to be as anticipated, estimated, described 
or intended. Ondine does not intend, and does not assume any obligation, to update this forward-looking 
information to reflect changes in assumptions or changes in circumstances or any other events affecting such 
information, other than as required by applicable law. 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biomedical Inc. 
Carolyn Cross 
Chairman and CEO 
(604) 669-0555 
ccross@ondinebio.com 
www.ondinebio.com 
 
OR 
 
Canaccord Genuity Limited, Nominated Adviser 
Mark Williams/Bhavesh Patel 
+4420 7050 6500 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this 
release. 
 
 
 
Ondine Biomedical Inc. 
 

Ondine Biomed (LSE:OBP)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024

Ondine Biomed (LSE:OBP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024